by pesbm | Jun 24, 2025 | News
The data support the EPISEEK™ test’s potential as an accurate and cost-effective solution for multi-cancer early detection through a simple blood draw. PHOENIX, AZ, UNITED STATES – June 2, 2025 /EINPresswire.com/ — Precision Epigenomics, a biotechnology...
by pesbm | Feb 21, 2025 | News
Tucson’s News 13 recently highlighted Precision Epigenomic’s groundbreaking work developing EPISEEK™, a multi-cancer early detection blood test. The segment focused on EPISEEK that looks for signals shared by more than 50 types of cancer through a simple blood draw,...
by pesbm | Jan 13, 2025 | News
Precision Epigenomics announced that the company presented data supporting the critical role of its melanoma classifier. TUCSON, Az. - Nov. 21, 2024 - /EINPresswire.com/ — Precision Epigenomics, the developer of the EPISEEK™ multi-cancer detection (MCD) test,...
by pesbm | Sep 10, 2024 | News
With this funding, Precision Epigenomics has raised more than $3.9M in investments helping move the company into the revenue stage. TUCSON, Az. - Sept. 10, 2024 - Precision Epigenomics Inc. announces the completion of a $1.5M Series A1 preferred stock round of funding...
by pesbm | Aug 27, 2024 | News
This award will lead to the development of EPISEEK-MPE, a multi-cancer detection test, using pleural fluid to detect cancer. Tucson, AZ—August 27, 2024—Precision Epigenomics Inc. (“Precision Epigenomics”), a molecular diagnostic healthcare company that features...
